FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385422022> ?p ?o ?g. }

• W4385422022 endingPage "3847" @default.
• W4385422022 startingPage "3847" @default.
• W4385422022 abstract "Background: Approximately 6% of women with breast cancer carry pathogenic germline variants in predisposition genes such as BRCA1 and BRCA2. Depending on personal and family cancer history, it is therefore recommended to test for hereditary breast cancer. Moreover, as shown by the phase III OlympiA trial, olaparib significantly improves overall survival in patients with HER2 negative (HER2−) early breast cancer who (1) carry a BRCA1 or BRCA2 germline mutation (gBRCA1/2-positive), (2) have received (neo)adjuvant chemotherapy and (3) are at high clinical risk. The objective of the current analysis was to determine the number of patients with early HER2− breast cancer who are at high clinical risk, according to the inclusion criteria of OlympiA, and to estimate how many of these patients would meet the criteria for hereditary cancer testing in a real-world analysis. Methods: All patients included in this retrospective analysis were treated for early breast cancer (eBC) at the Department of Gynecology and Obstetrics, Ulm University Hospital, Germany, and the Department of Women’s Health at Tuebingen University Hospital, Germany, between January 2018 and December 2020. Patients were identified as high risk, in line with the clinicopathological determiners used in the OlympiA trial. The criteria of the German Consortium for Hereditary Breast and Ovarian Cancer were used to identify patients who qualify for hereditary cancer testing. Results: Of 2384 eligible patients, 1738 patients (72.9%) showed a hormone receptor positive (HR+)/HER2− tumor biology, 345 patients (14.5%) displayed HER2+ breast cancer and 301 patients (12.6%) suffered from HR-/HER2− breast cancer (TNBC). Of 2039 HER2− breast cancer patients, 271 patients (13.3%) were at high clinical risk. This cohort encompassed 130 of the 1738 patients with HR+/HER2− breast cancer (7.5%) and 141 of 301 patients with TNBC (46.8%). A total of 121 of 271 patients (44.6%) with high clinical risk met the criteria for hereditary cancer testing (34 of 130 (26.2%) HR+/HER2− patients and 87 of 141 (61.7%) patients with TNBC). Conclusion: Approximately one in ten patients with HR+/HER2−, and half of the patients with TNBC, meet the high-risk criteria according to OlympiA. Half of these patients do not meet the criteria for hereditary cancer testing and should therefore be tested for the presence of gBRCA1/2 mutations, irrespective of their own or family cancer history. The overall number of patients with early breast cancer benefiting from olaparib needs to be investigated in future studies." @default.
• W4385422022 created "2023-08-01" @default.
• W4385422022 creator A5008649645 @default.
• W4385422022 creator A5013148496 @default.
• W4385422022 creator A5017949379 @default.
• W4385422022 creator A5019276717 @default.
• W4385422022 creator A5023008141 @default.
• W4385422022 creator A5024625013 @default.
• W4385422022 creator A5030131864 @default.
• W4385422022 creator A5031064268 @default.
• W4385422022 creator A5040637036 @default.
• W4385422022 creator A5044362607 @default.
• W4385422022 creator A5045891981 @default.
• W4385422022 creator A5059250883 @default.
• W4385422022 creator A5066355377 @default.
• W4385422022 creator A5069633271 @default.
• W4385422022 creator A5069749411 @default.
• W4385422022 creator A5081646134 @default.
• W4385422022 creator A5084720156 @default.
• W4385422022 creator A5085385776 @default.
• W4385422022 creator A5088582853 @default.
• W4385422022 creator A5092781555 @default.
• W4385422022 creator A5092781556 @default.
• W4385422022 date "2023-07-28" @default.
• W4385422022 modified "2023-10-18" @default.
• W4385422022 title "Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers" @default.
• W4385422022 cites W1991808212 @default.
• W4385422022 cites W2002873340 @default.
• W4385422022 cites W2112358255 @default.
• W4385422022 cites W2144335178 @default.
• W4385422022 cites W2264000214 @default.
• W4385422022 cites W2289657957 @default.
• W4385422022 cites W2298876126 @default.
• W4385422022 cites W2517421365 @default.
• W4385422022 cites W2618058692 @default.
• W4385422022 cites W2766137080 @default.
• W4385422022 cites W2789481433 @default.
• W4385422022 cites W2805734855 @default.
• W4385422022 cites W2928807055 @default.
• W4385422022 cites W2947918745 @default.
• W4385422022 cites W2957101013 @default.
• W4385422022 cites W3010039170 @default.
• W4385422022 cites W3124119591 @default.
• W4385422022 cites W3165576985 @default.
• W4385422022 cites W3179495039 @default.
• W4385422022 cites W3206169364 @default.
• W4385422022 cites W3214263430 @default.
• W4385422022 cites W4206349107 @default.
• W4385422022 cites W4214822522 @default.
• W4385422022 cites W4226218519 @default.
• W4385422022 cites W4292604276 @default.
• W4385422022 cites W4304084160 @default.
• W4385422022 cites W4307401062 @default.
• W4385422022 cites W4308121578 @default.
• W4385422022 cites W4311018441 @default.
• W4385422022 cites W4379645953 @default.
• W4385422022 doi "https://doi.org/10.3390/cancers15153847" @default.
• W4385422022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37568663" @default.
• W4385422022 hasPublicationYear "2023" @default.
• W4385422022 type Work @default.
• W4385422022 citedByCount "0" @default.
• W4385422022 crossrefType "journal-article" @default.
• W4385422022 hasAuthorship W4385422022A5008649645 @default.
• W4385422022 hasAuthorship W4385422022A5013148496 @default.
• W4385422022 hasAuthorship W4385422022A5017949379 @default.
• W4385422022 hasAuthorship W4385422022A5019276717 @default.
• W4385422022 hasAuthorship W4385422022A5023008141 @default.
• W4385422022 hasAuthorship W4385422022A5024625013 @default.
• W4385422022 hasAuthorship W4385422022A5030131864 @default.
• W4385422022 hasAuthorship W4385422022A5031064268 @default.
• W4385422022 hasAuthorship W4385422022A5040637036 @default.
• W4385422022 hasAuthorship W4385422022A5044362607 @default.
• W4385422022 hasAuthorship W4385422022A5045891981 @default.
• W4385422022 hasAuthorship W4385422022A5059250883 @default.
• W4385422022 hasAuthorship W4385422022A5066355377 @default.
• W4385422022 hasAuthorship W4385422022A5069633271 @default.
• W4385422022 hasAuthorship W4385422022A5069749411 @default.
• W4385422022 hasAuthorship W4385422022A5081646134 @default.
• W4385422022 hasAuthorship W4385422022A5084720156 @default.
• W4385422022 hasAuthorship W4385422022A5085385776 @default.
• W4385422022 hasAuthorship W4385422022A5088582853 @default.
• W4385422022 hasAuthorship W4385422022A5092781555 @default.
• W4385422022 hasAuthorship W4385422022A5092781556 @default.
• W4385422022 hasBestOaLocation W43854220221 @default.
• W4385422022 hasConcept C104317684 @default.
• W4385422022 hasConcept C121608353 @default.
• W4385422022 hasConcept C126322002 @default.
• W4385422022 hasConcept C131872663 @default.
• W4385422022 hasConcept C143998085 @default.
• W4385422022 hasConcept C182979987 @default.
• W4385422022 hasConcept C185592680 @default.
• W4385422022 hasConcept C2779962180 @default.
• W4385422022 hasConcept C2780194787 @default.
• W4385422022 hasConcept C2780427987 @default.
• W4385422022 hasConcept C2780673598 @default.
• W4385422022 hasConcept C2781179581 @default.
• W4385422022 hasConcept C29456083 @default.
• W4385422022 hasConcept C530470458 @default.

• next